Insight2019-11-12T12:18:48+00:00
Loading...

Latest news and thought leadership

All the latest from Deallus pharmaceutical and life science industry experts

Latest White Papers

Let’s talk about NASH

November 5th, 2019|Categories: White Paper|Tags: , |

Several promising candidates are currently competing in a multi-billion-dollar race. NASH, or non-alcoholic steatohepatitis, affects millions of patients world-wide and by 2020 is projected to replace hepatitis C as the number one reason for liver transplantation in the United States. Multiple drug developers have taken on the challenge and a variety of different approaches are currently in the pipeline to tackle this complex, silent disease. Now all eyes are on the finish line to see who will be the first to enter this lucrative and untapped market.

Antimicrobial Resistance

October 26th, 2019|Categories: White Paper|Tags: , |

Lack of innovation surrounding the development of new antibiotics has resulted in an alarming situation, given the rising threat of antimicrobial resistance (AMR). As a result, there is no single or straightforward way to combat AMR, nor to galvanize development of novel antibiotics. Although some positive measures have been introduced, further - and larger scale - action is needed. We take a look at what pharma and the larger healthcare industry needs to do in order to combat this looming threat.

Copay Accumulator Programs & Pharma

August 5th, 2019|Categories: White Paper|Tags: , , |

Dynamics between pharma and the market-based healthcare sector it serves have invariably been complex, with one of the biggest drivers of that complexity being effective management of patient demand and payer systems. The newest stratagem in this push and pull is the copay accumulator program, or CAP. We take a closer look at CAPs and how they might affect your brand in the near future.

Latest Videos

Deallus Keynote at Pharma CiMi.CON EU 2019

October 16th, 2019|Categories: Video|Tags: , |

Jonas gives a keynote speech that delves into the importance of strategic intelligence for pharma given today’s dynamic and disruptive marketplace. He explores how competitive and strategic intelligence are related, how to build more strategically focused engagements, and how to help decision makers realize the value in strategic partnerships with their intelligence teams.

Latest News

Gene therapy through different lenses

Categories: Thought Piece|

After decades of clinical research and numerous setbacks, the promise of gene therapy is now much more than a glimmering hope on the horizon. Gene therapy is poised to revolutionize medicine as it presents the opportunity to remove or change the content of an individual’s genetic code in order to potentially treat or cure disease. We explore gene therapy from a few different lenses to give a full picture of where this innovation currently stands.

Head to head trials in elbow to elbow markets

Categories: Thought Piece|

Head to head trials are proving to be a powerful mechanism for the testing of competitive medicines. A tactic for those already on the market who are eager to expand their market share, it offers the promise of considerable commercial advantage. We explore what needs to be known about head to head trials, and how they might be put to use for products operating in a saturated, competitive market.

Latest Case Studies

Competitive Simulation Strategy

Tags: , , , |

Our client was facing a major pharma player in a highly lucrative and rare disease space. They wanted to ensure that they had a chance to analyze their competition’s launch plan and plans for targeting their own product, but they did not have the time to conduct a cross-functional, traditional workshop. They came to us to discuss their goals and assess the most strategic way forward. This case study explores this launch scenario in which we put a unique spin on the traditional competitive simulation approach for our client.

Launching for Success

Tags: , , , |

Our client was a small-to medium-sized pharmaceutical company with a limited development pipeline who was in the process of launching their first product, an orphan drug, for treating a rare disease. They were a relatively small organisation with no prior knowledge of the competitive environment and no standardised launch planning process or procedures. This case study explores how our client engaged us to help them understand their competitive landscape, streamline launch efforts across markets, and stress test and revise their launch planning strategies.

Asset Evaluation

Tags: , , , , |

Our client was a medium-sized pharma company interested in launching an antibiotic asset for treating pathogens with limited treatment options in Central and Southern Europe, as well as the Middle East. Their antibiotic was a particularly strong candidate for commercialization due to its novelty in tackling multi-resistant antibiotic pathogens and the extremely high unmet demands in the targeted regions. Our client engaged us to work with their business intelligence managers in order to evaluate the commercial value of the asset and to advise on the best strategic route to commercialization.

Upcoming Events

Pharma CiMi.CON 2019

Lead Sponsors at Pharma CiMi US

November 7-8, 2019
Boston, Massachusetts, USA

Learn more

Exhibitors at PharmaCI Asia

December 5-6, 2019
Singapore, Southeast Asia

Learn more
PharmaCI Conference Europe

Exhibitors at PharmaCI Europe

February/March, 2020
Dates & Location to be confirmed

Learn more

Register your email address to be alerted to our latest news